Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1.

Saved in:
Bibliographic Details
Title: Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1.
Authors: Faulk KE; Center for Cancer and Blood Disorders, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, CO., Kairalla JA; Department of Biostatistics, University of Florida, Gainesville, FL., Hibbitts E; Department of Biostatistics, University of Florida, Gainesville, FL., Long-Boyle J; Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, San Francisco, CA., Devidas M; Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN., August A; Division of Hematology, Oncology, and Bone Marrow Transplantation, Children's Mercy Kansas City, Kansas City, MO., Gore L; Center for Cancer and Blood Disorders, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, CO., Raetz E; Department of Pediatrics, New York University Langone Health, New York, NY., Hunger SP; Division of Oncology and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA., Loh ML; Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children's Research Institute, Seattle, WA.; Department of Pediatrics, Seattle Children's Hospital, Fred Hutch Cancer Center, University of Washington, Seattle, WA., Teachey DT; Division of Oncology and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA., Brown P; Bristol Myers Squibb, Princeton, NJ., Breese EH; Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH., Kotecha RS; Department of Clinical Haematology, Oncology, Blood and Marrow Transplantation, Perth Children's Hospital, Perth, WA, Australia.; Leukaemia Translational Research Laboratory, WA Kids Cancer Centre, The Kids Research Institute Australia, University of Western Australia, Perth, WA, Australia.; Curtin Medical School, Curtin University, Perth, WA, Australia., Guest E; Division of Hematology, Oncology, and Bone Marrow Transplantation, Children's Mercy Kansas City, Kansas City, MO.
Source: Blood advances [Blood Adv] 2026 Jan 13; Vol. 10 (1), pp. 70-74.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025017013